Yang Na, Zhou Guanlun, Cheng Xiaoliang, He Jun, Chen Yan, Chen Chao, Li Meijuan, Ge Jiajia, Wang Min, Zhang Tianqi, Ge Weihong, Zhu Huaijun, Han Guorong
Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
Front Pharmacol. 2021 Aug 13;12:734760. doi: 10.3389/fphar.2021.734760. eCollection 2021.
Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that has been approved for the treatment of chronic hepatitis B virus (HBV) infection. It has greater plasma stability and more favorable renal safety than tenofovir disoproxil fumarate (TDF), the first approved oral prodrug of TFV. However, the distribution of TFV in the breast milk of mothers treated with TAF is still unclear. In this study, sixteen participants with chronic HBV infection were enrolled and received antiretroviral therapy with 25 mg of TAF or 300 mg of TDF daily from 24 to 28 weeks of gestation until the 4th week postpartum. For the first time, the distribution of TFV in the breast milk of mothers with chronic HBV infection treated with TAF and its difference from TDF were evaluated by using a sensitive UPLC-MS/MS method. Chromatographic separation was achieved on a Waters ACQUITY UPLC BEH C18 column (1.7 µm 2.1 × 100 mm). Mass spectrometry analysis was performed in positive electrospray ionization mode and multiple reaction monitoring (MRM) conditions of transitions m/z 288.1→176.2 for TFV. This method was linear from 0.5 to 500 ng/ml. Surprisingly, on the third postpartum day, the median Cmax of TFV in the breast milk was much higher in the mothers treated with TAF (101.2 ng/ml) than TDF (21.6 ng/ml) at a similar Tmax of 4 h. Accordingly, the median AUC0-8 value was 755.6 ng h/mL in the mothers taking TAF, which was at a 5-fold higher level than TDF. The concentration of TFV in the breast milk of mothers in both groups decreased with increasing lactation time. These data indicated that there was a relatively higher exposure of TFV in the breast milk of mothers taking TAF, despite the lower dosage compared to TDF. This study provides support for further evaluating the safety of breastfeeding after the administration of TAF and TDF.
替诺福韦艾拉酚胺(TAF)是替诺福韦(TFV)的一种新型前体药物,已被批准用于治疗慢性乙型肝炎病毒(HBV)感染。与首个获批的TFV口服前体药物富马酸替诺福韦二吡呋酯(TDF)相比,它具有更高的血浆稳定性和更良好的肾脏安全性。然而,接受TAF治疗的母亲的母乳中TFV的分布情况仍不清楚。在本研究中,招募了16名慢性HBV感染参与者,从妊娠24至28周开始至产后第4周,每天接受25 mg TAF或300 mg TDF的抗逆转录病毒治疗。首次使用灵敏的超高效液相色谱-串联质谱(UPLC-MS/MS)方法评估了接受TAF治疗的慢性HBV感染母亲的母乳中TFV的分布及其与TDF的差异。在Waters ACQUITY UPLC BEH C18柱(1.7 µm,2.1×100 mm)上实现色谱分离。质谱分析在正电喷雾电离模式和TFV的m/z 288.1→176.2跃迁的多反应监测(MRM)条件下进行。该方法在0.5至500 ng/ml范围内呈线性。令人惊讶的是,在产后第三天,接受TAF治疗的母亲母乳中TFV的Cmax中位数(101.2 ng/ml)比TDF(21.6 ng/ml)高得多,Tmax相似,均为4小时。相应地,服用TAF的母亲的AUC0-8中位数为755.6 ng h/mL,比TDF高5倍。两组母亲母乳中TFV的浓度均随着哺乳时间的增加而降低。这些数据表明,尽管TAF的剂量低于TDF,但服用TAF的母亲的母乳中TFV的暴露量相对较高。本研究为进一步评估TAF和TDF给药后母乳喂养的安全性提供了支持。